Radient Technologies’ (RTI.V) bioU products will now be available for patients to use during the recently announced University Health Networks’ (UHN) medical cannabis real world evidence study (MC-RWE), according to a press release today.
This study comes in conjunction with Medical Cannabis by Shoppers, and involves a nationwide clinical trial to determine the effects of medical cannabis on issues related to pain, sleep and anxiety.
“Radient strongly believes that consistency, safety and standardization are key elements for all medical products, and are excited to partner with UHN, Shoppers and TruTrace on this groundbreaking study, Providing patients and medical professionals with trusted products that deliver repeatable results is a crucial step in having cannabis incorporated into medical treatments and is at the heart of all Radient products. Shoppers is creating a standard for medical cannabis, which along with the data from these clinical trials, will increase the confidence of both doctors and patients in using cannabis for medical purposes,” said Denis Taschuk, chief executive officer of Radient Technologies.
Radient is an industrial grade extraction service, manufacturing cannabinoid formulations, ingredients and products. They use an extraction and processing platform that recovers 99% of cannabinoids from the cannabis plant.
The company’s bioU brand is developed exclusively for Medical Cannabis by Shoppers. It comes in three oral spray formulations, and can be found on the Medical Cannabis by Shoppers site, and will be available to participants in the MC-RWE study, giving patients options in both THC and CBD products in a standard dose format. All bioU products have been tested, and the results registered on TruTrace Technologies (TRU.C) software platform, and blended with the Medical Cannabis by Shoppers.